GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Plus Therapeutics Inc (NAS:PSTV) » Definitions » Shiller PE Ratio

PSTV (Plus Therapeutics) Shiller PE Ratio : (As of Apr. 28, 2025)


View and export this data going back to 2000. Start your Free Trial

What is Plus Therapeutics Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Plus Therapeutics Shiller PE Ratio Historical Data

The historical data trend for Plus Therapeutics's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Plus Therapeutics Shiller PE Ratio Chart

Plus Therapeutics Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Plus Therapeutics Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Plus Therapeutics's Shiller PE Ratio

For the Biotechnology subindustry, Plus Therapeutics's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Plus Therapeutics's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Plus Therapeutics's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Plus Therapeutics's Shiller PE Ratio falls into.


;
;

Plus Therapeutics Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Plus Therapeutics's E10 for the quarter that ended in Dec. 2024 is calculated as:

For example, Plus Therapeutics's adjusted earnings per share data for the three months ended in Dec. 2024 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Dec. 2024 (Change)*Current CPI (Dec. 2024)
=-0.67/133.1571*133.1571
=-0.670

Current CPI (Dec. 2024) = 133.1571.

Plus Therapeutics Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201503 -21,238.498 99.621 -28,388.131
201506 3,375.000 100.684 4,463.526
201509 1,125.000 100.392 1,492.176
201512 -2,142.277 99.792 -2,858.528
201603 -3,075.000 100.470 -4,075.410
201606 -3,225.000 101.688 -4,223.028
201609 -1,950.000 101.861 -2,549.124
201612 -1,800.000 101.863 -2,352.998
201703 -2,475.000 102.862 -3,203.935
201706 -1,455.000 103.349 -1,874.652
201709 -1,042.500 104.136 -1,333.034
201712 -1,507.500 104.011 -1,929.932
201803 -547.500 105.290 -692.410
201806 -442.500 106.317 -554.212
201809 -414.450 106.507 -518.155
201812 -113.083 105.998 -142.058
201903 -133.800 107.251 -166.120
201906 -310.050 108.070 -382.026
201909 -0.450 108.329 -0.553
201912 3.417 108.420 4.197
202003 -4.200 108.902 -5.135
202006 -6.750 108.767 -8.264
202009 -5.850 109.815 -7.093
202012 -10.950 109.897 -13.268
202103 -4.950 111.754 -5.898
202106 -3.750 114.631 -4.356
202109 -4.200 115.734 -4.832
202112 -4.050 117.630 -4.585
202203 -2.850 121.301 -3.129
202206 -3.560 125.017 -3.792
202209 -2.850 125.227 -3.030
202212 -2.360 125.222 -2.510
202303 -2.070 127.348 -2.164
202306 -0.590 128.729 -0.610
202309 -1.000 129.860 -1.025
202312 -0.700 129.419 -0.720
202403 -0.750 131.776 -0.758
202406 -0.710 132.554 -0.713
202409 -0.370 133.029 -0.370
202412 -0.670 133.157 -0.670

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Plus Therapeutics  (NAS:PSTV) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Plus Therapeutics Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Plus Therapeutics's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Plus Therapeutics Business Description

Traded in Other Exchanges
N/A
Address
2710 Reed Road, Suite 160, Houston, TX, USA, 77051
Plus Therapeutics Inc is a clinical-stage pharmaceutical company that focuses on discovering, developing, and delivering complex treatments for patients with cancer and rare diseases. The company is working on a range of potential products, with its main programs targeting recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). One of its key candidates, rhenium (186Re) obisbemeda, is specifically designed to treat central nervous system (CNS) cancers such as GBM, LM, and pediatric brain cancers (PBC).
Executives
Richard J Hawkins director 950 TOWER LANE, SUITE 900, FOSTER CITY CA 94404-2125
Greg Petersen director 3100 MAIN STREET, SUITE 900, HOUSTON TX 77002
Howard Clowes director 217 DWIGHT ROAD, BURLINGAME CA 94010
Marc H Hedrick officer: President C/O CYTORI THERAPEUTICS, INC., 3020 CALLAN ROAD, SAN DIEGO CA 92121
Sims Andrew John Hugh Macintyre officer: Chief Financial Officer 4200 MARATHON BOULEVARD, SUITE 200, AUSTIN TX 78756
Robert P Lenk director LUNA INNOVATIONS INCORPORATED, 2851 COMMERCE STREET, BLACKSBURG VA 24060
Norman D. Lafrance officer: CHIEF MEDICAL OFFICER MOLECULAR INSIGHT PHARMCEUTICALS, INC., 160 SECOND STREET, CAMBRIDGE MA 02142
Es-johansson An Van director 6863 BEE CAVE ROAD, SUITE 200, AUSTIN TX 78736
Ag Postfinance 10 percent owner MINGERSTRASSE 20, BERN V8 3030
Bank Sa Swissquote 10 percent owner CHEMIN DE LA CRETAUX 33, GLAND V8 1196
Anthony Gregg Lapointe director PO BOX 83216, GAITHERSBURG MD 20883-3216
Ron Martell director PONIARD PHARMACEUTICALS, INC., 750 BATTERY STREET, SUITE 330, SAN FRANCISCO CA 94111
Mark Marino officer: Chief Medical Officer C/O CYTORI THERAPEUTICS, INC., 3020 CALLAN ROAD, SAN DIEGO CA 92121
John David Harris officer: VP and GM of Cell Therapy 3020 CALLAN ROAD, SAN DIEGO CA 92121
Gail K Naughton director C. R. BARD, INC., 730 CENTRAL AVENUE, MURRAY HILL NJ 07974

Plus Therapeutics Headlines

From GuruFocus